Brief: Menlo Therapeutics signs license agreement with Japan Tobacco, Torii Pharma for NK-1 receptor antagonist

Torii Pharmaceutical Co

10/08/2016 18:00

Aug 10 (Reuters) - Menlo Therapeutics Inc :   
    * Menlo Therapeutics signs exclusive license agreement with 
Japan Tobacco and Torii Pharmaceuticals for development and 
commercialization of NK-1 receptor antagonist in Japan 
    * Entered into license agreement with Japan Tobacco Inc. and 
Torii Pharmaceutical for development,commercialization of 
serlopitant in Japan 
    * JT,Torii to pay co upfront licensing fees,payments upon 
achievement of certain milestones, royalties based on future 
sales in Japan 
 
Source text for Eikon:  ID:nPn5hH2Rxa  
 
 ((Bangalore.newsroom@thomsonreuters.com ;))